JAMES C BLAIR
CIK 1024000 · last filed 2021-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$556.80M
Companies
24
Total Filings
127
Lifetime Open-Market Net
$73.71M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Clovis Oncology, Inc. (CLVS) Delisted | Director | 53,439 | $0.08 | $4.3K | -$62.21M | 22 | 2021-06-11 |
| LIFE | Director | 129,130 | $19.84 | $2.56M | $0 | 7 | 2019-05-10 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | 10%+ Owner | 3,482,033 | $38.22 | $133.08M | $0 | 3 | 2017-12-20 |
| CoLucid Pharmaceuticals, Inc. (CLCD) Delisted | 10%+ Owner | 3,168 | — | — | -$10.4K | 2 | 2016-08-03 |
| Evoke Pharma Inc (OMED) Delisted | 10%+ Owner | 35,296 | — | — | -$1.71M | 5 | 2016-04-21 |
| SNDX | 10%+ Owner | 1,743,854 | $19.22 | $33.52M | $0 | 1 | 2016-03-08 |
| GKOS | 10%+ Owner | 2,077,660 | $161.66 | $335.87M | $0 | 1 | 2015-07-01 |
| ESPR | 10%+ Owner | 2,597,397 | $3.18 | $8.26M | $74.00M | 2 | 2014-10-21 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 1,987,049 | — | — | $0 | 1 | 2014-03-17 |
| TNDM | 10%+ Owner | 318,906 | $18.59 | $5.93M | $0 | 1 | 2013-11-19 |
| VCYT | 10%+ Owner | 3,063,294 | $55.71 | $170.66M | $0 | 1 | 2013-11-04 |
| Tobira Therapeutics, Inc. (RGDO) Delisted | 10%+ Owner | 513 | — | — | $3.00M | 1 | 2013-08-28 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | 10%+ Owner | 47,963 | — | — | $8.00M | 1 | 2013-07-16 |
| ALIMERA SCIENCES INC (ALIM) Delisted | 10%+ Owner | 262,599 | $5.54 | $1.45M | -$1.71M | 5 | 2013-06-20 |
| ZOGENIX, INC. (ZGNX) Delisted | Director | 1,240,417 | $26.68 | $33.09M | $16.40M | 6 | 2013-06-19 |
| CADENCE PHARMACEUTICALS INC (CADX) Delisted | Director | 2,417,824 | — | — | $8.10M | 24 | 2013-06-13 |
| ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | 10%+ Owner | 5,772,968 | — | — | $0 | 3 | 2013-01-18 |
| Durata Therapeutics, Inc. (DRTX) Delisted | 10%+ Owner | 2,227,596 | — | — | $7.06M | 1 | 2012-07-24 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | 10%+ Owner | 7,001 | — | — | $24.29M | 14 | 2011-12-22 |
| Paratek Pharmaceuticals, Inc. (NOVC) Delisted | Director | 67,875 | — | — | -$514.6K | 4 | 2009-01-30 |
| Volcano Corp (VOLC) Delisted | Director | 1,939,456 | — | — | -$985.0K | 10 | 2008-07-18 |
| PHARMION CORP (PHRM) Delisted | Director | — | — | — | $0 | 1 | 2007-06-08 |
| NUVASIVE INC (NUVA) Delisted | Director | 3,457 | $39.75 | $137.4K | $0 | 3 | 2007-05-29 |
| SENORX INC (SENO) Delisted | 10%+ Owner | 24,665 | — | — | $0 | 1 | 2007-04-03 |
Recent Filings · Page 8 of 13
127 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-01-18 | ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | Other (J) | −933,538 | $0 | EDGAR |
| 2012-07-24 | Durata Therapeutics, Inc. (DRTX) Delisted | Mixed | +3,028,438 | $7.06M | EDGAR |
| 2012-06-18 | Clovis Oncology, Inc. (CLVS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-06-14 | CADENCE PHARMACEUTICALS INC (CADX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-06-08 | ZOGENIX, INC. (ZGNX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-06-04 | ACHILLION PHARMACEUTICALS INC (ACHN) Delisted | Other (J) | −1,106,566 | $0 | EDGAR |
| 2012-05-01 | ZOGENIX, INC. (ZGNX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2012-03-27 | — | Sell (S) | −1,695,717 | -$8.75M | |
| 2011-12-22 | Orexigen Therapeutics, Inc. (OREX) Delisted | Buy (P) | +469,147 | $680.3K | EDGAR |
| 2011-11-21 | Clovis Oncology, Inc. (CLVS) Delisted | Mixed | +3,041,950 | $12.11M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.